

To the extent that O'Connell's letter is accusatory, I find it objectionable. We need to make more peace, not war, on issues of drugs in our society. My preference is to consider alternative perspectives respectfully and to challenge them forcefully when necessary. As I conclude in my review, "this is especially the case when we are dealing with problems as complex as those involved with substance use disorders."

Edward J. Khantzian, MD
Tewksbury Hospital
Tewksbury, Mass

In Reply.—Dr O'Connell complains that my book, *The Selfish Brain: Learning From Addiction*, is not referenced. He may be reassured to know that the book was peer reviewed by the publisher and the American Psychiatric Press and that JAMA's reviewer, Dr Khantzian, is a distinguished opponent of many of my drug policy recommendations, which he makes clear in his review. The book lists 43 recommended books on related topics in the section "Bibliotherapy." Finally, O'Connell and other readers seeking more citations can find ample references in my many published articles on drug policy, including those cited below.¹⁻⁴

The Selfish Brain is not a drug policy book. Instead, it offers an integrated, comprehensive understanding of the uniquely human and 20th-century problems of addiction to alcohol and other drugs. The most important features of the book are the recognition of the newly elucidated biology of reward as the principal biological root of addiction and a single-minded focus on the vital role of the 12-step programs, including Alcoholics Anonymous, in promoting lifelong recovery from addiction.

O'Connell misunderstands my support for drug testing. Testing for alcohol and other drugs is important for both prevention and treatment, because denial is, along with loss of control or unmanageability, 1 of the 2 principal characteristics of addiction. It is only when denial and dishonesty are stripped away from addictive behavior that the healing forces of recovery can begin the transformation of the addict and the addict's family. I have known many addicted people who date the beginning of their recovery from the time they were "caught" in the criminal justice system, the workplace, or elsewhere as a result of a positive drug test result.

I am grateful to the American Psychiatric Press for publishing the book, to JAMA for having it reviewed, and to O'Connell for bringing additional readers to the book.

Robert L. DuPont, MD
Institute for Behavior and Health, Inc
Rockville, Md

1. DuPont RL, McGovern JP. *A Bridge to Recovery: An Introduction to 12-Step Programs*. Washington, DC: American Psychiatric Press; 1994.
2. DuPont RL, Voth EA. Drug legalization, harm reduction, and drug policy. *Ann Intern Med*. 1995;123:461-465.
3. DuPont RL, Gold MS. Withdrawal and reward: implications for detoxification and relapse prevention. *Psychiatr Ann*. 1995;25:663-668.
4. DuPont RL. Harm reduction and decriminalization in the United States: a personal perspective. *Subst Use Misuse*. 1996;31:1929-1945.

The Spectrum of Medical Care: Curative, Rehabilitative, and Palliative

To the Editor.—The Editorial by Dr Fox¹ insightfully explains the need for reforms in medical education that will enhance a flexible mix of curative and palliative approaches in medical practice, approaches fashioned to the needs, value systems, and specifics of individual patients rather than to diseases and organ systems. "For most patients neither a purely curative model nor a purely palliative care model is altogether suitable, . . . [since] most have chronic disabling conditions as well [as curable conditions]." Fox concludes, "Reframing the problem with medical education in terms of its relative

emphasis on the various models of medical care may help to marshal resources to effect essential changes in medical school curricula and graduate medical education programs." I agree wholeheartedly with this approach, but I have a suggestion that the semantics of her curative vs palliative care models need modification.

The incorporation of rehabilitative and restorative care—efforts to improve function and restore homeostasis in chronic, disabling conditions—within the palliative paradigm is neither appropriate nor rigorous. Rehabilitative and restorative care and the general treatment of chronic diseases are a major aspect of medical and health care and describe the approach to patients that fills the huge gulf between curative and palliative care.

While palliative care usually focuses on comfort, alleviation of pain, and emotional support in coping with dying, death, and loss, rehabilitative care focuses on a "work ethic" and often involves a contract-driven relationship between the patient and clinicians. While we want our hospice patients to be as free of pain as possible, our rehabilitating patients may be presented the time-honored slogan "no pain, no gain" to motivate them to "come back" to full life.

Reforms in medical education are being discussed in many venues and are desperately needed. But if those reforms are to maintain a high ethical standard, they will have to incorporate team approaches to patient support and rehabilitation that are not limited to palliative and curative care education. In fact, the broadened definition of palliation presented by Fox causes confusion. Most medical care in the current and coming era belongs conceptually—although closer to the palliative approach with its sensitivity to the wants and needs of the individual—within a different paradigm, one that requires an exclusive definition and for which practical experiential and didactic teaching models already exist and could be readily incorporated into medical school and residency training.

Marc Sapir, MD, MPH
Center for Elders Independence
Oakland, Calif

1. Fox E. Predominance of the curative model of medical care: a residual problem. *JAMA*. 1997;278:761-764.

In Reply.—Dr Sapir's comments reflect a misreading of my Editorial.¹ He represents me as supporting a "broadened definition" of palliative care in which rehabilitative and restorative care are subsumed within the palliative care paradigm, and he also seems to misconstrue my remarks to suggest that all medical care is either curative or palliative. In fact, I argued precisely the opposite, that the curative model and the palliative care model are 2 diametric extremes:

It is a mistake to view the curative model and the palliative care model as the only 2 options available. Instead, the two models represent opposite ends of a spectrum in which limitless variations are possible. . . . Between the curative model and the palliative model lies an unnamed approach that supports all legitimate goals of medicine—health promotion, prevention, rehabilitation, life preservation, comfort, and care—and is willing to combine them in whatever manner best reflects the values of an individual patient. The flexibility of this approach makes it appropriate for all cases in which neither the curative model nor the palliative care model alone will do.¹

Perhaps a misunderstanding was created by my reference to the World Health Organization's definition of palliative care: "the active total care. . . of patients whose disease is not responsive to curative treatment." Taken literally, these words might be interpreted to mean that the care of all patients with chronic diseases is properly characterized as palliative. But my personal concept of palliative care is not nearly so broad. Rather, in my view, the palliative care model is applied most

appropriately to patients who are entering the final, predictably progressive course toward death.

Thus, I concur with Sapir that rehabilitative care within the palliative care paradigm. However, I disagree with his assertion that rehabilitative care "fills the gap between curative and palliative care." Just as the curative and the palliative care model are each characterized by a distinct set of assumptions, attitudes, and values, so is the rehabilitative model. As Sapir so aptly describes, the rehabilitative care focuses on a "work ethic" and embodies the goal of "no pain, no gain." Although rehabilitative care clearly has value for many patients whose needs are unmet by pure palliative models, no approach that focuses on a single predetermined goal would suit them all.

Finally, Sapir argues that rehabilitative care is a distinct conceptual paradigm that warrants its own name. Although I agree that meaningful differences exist between rehabilitative, curative, and palliative care, I do not think this misses the point. The central thesis of my Editorial is that the current medical education system is excessively oriented toward cure at the expense of other important goals such as palliation and rehabilitation. I suggest that we stop trying to fit patients into predefined models and instead focus our models to the patients we serve.

Ellen Fox, MD
American Medical Association
Chicago, Ill

1. Fox E. Predominance of the curative model of medical care: a residual problem. *JAMA*. 1997;278:761-764.

Preserving the Clinical Research Ecosystem

To the Editor.—The Commentary by Drs T. M. Moskowitz¹ on preserving the clinical research ecosystem should be applauded. In more than 40 years of pharmaceutical research and development, I have had the good fortune of seeing 20 new drugs enter the marketplace, I have been impressed by the important impact that good clinical research has had on the development process. In essentially every instance, we were able to carry out sophisticated early phase studies that markedly shortened the time required for development and improved the odds of approval for many drugs, especially frustrating in this day and age to witness the time between the high-caliber end points that we set and the time measure in the process of drug discovery and development (eg, cytokine levels, gene function) and available to carry out such work.

Financial belt-tightening is occurring across the spectrum from the National Institutes of Health to the pharmaceutical industry. The call for a top-level assessment to address the serious problem of the reduction of research personnel and facilities is indeed appropriate. At the same time, the situation is frightening, to say the least, because the budgetary restriction is so prevalent and a decision to reduce research capability will easily go unnoticed in the future because of the long lag time inherent in drug discovery and development. If all clinical research in drug development were to cease now, for example, it would require 6 to 10 years before it was clearly evident at large and to many physicians that the next generation of new drugs is simply not going to appear as expected.

The cross section of professional societies, medical organizations that was noted in the article, and a consortium that places appropriate professional and political pressure on the politicians and the directors of managed health